Targacept to pursue failed depression candidate in overactive bladder
This article was originally published in Scrip
Executive Summary
Targacept is hoping to breathe new life into its former antidepressant candidate TC-5214. It now has plans to pursue its development as a treatment for overactive bladder (OAB) and intends to start a Phase IIb study in the first half of next year.